Skip to main content
Eli LillyIn development

Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

Eli Lilly and Company announced positive Phase 3 clinical trial results for Foundayo (orforglipron) for the treatment of moderate-to-severe obstructive sleep apnea.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or mild disease Foundayo also reduced sleep apnea-specific hypoxic burden by up to an average of 55.9%, improving oxygen levels during sleep Lilly plans to submit Foundayo to the U.S. FDA for moderate-to-severe obstructive sleep apnea by the end of 2026 INDIANAPOLIS, Nov. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight, with and without the use of positive airway pressure (PAP) therapy. At 52 weeks, Foundayo met the primary endpoint, significantly reducing the apnea-hypopnea index (AHI), the standard measure of sleep apnea severity, as well as improving weight and other cardiovascular risk factors. 1 The results were presented today at the American Heart Association (AHA) Scientific Sessions 2026 and simultaneously published in JAMA. OSA affects an estimated 936 million adults worldwide, and most have never been diagnosed. 2 In people with OSA, the airway repeatedly collapses during sleep, causing drops in...

Keep reading with a free account

The rest of this article, and every signal for Eli Lilly, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Foundayo
Takes effect
Nov 9, 2026
Location
Indianapolis, Indiana, United States

The full record

From the Signal API record

Details

Ticker
NYSE:LLY

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Nov 9, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/3656cce3-7628-ac64-bc11-0847d88a70f6 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "3656cce3-7628-ac64-bc11-0847d88a70f6",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-09T14:30:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/lillys-foundayo-orforglipron-significantly-reduced-obstructive-sleep-apnea-severity-reinforcing-its-potential-to-improve-health-beyond-weight-loss-302932877.html",
    "title": "Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss",
    "ticker": "NYSE:LLY",
    "excerpt": "In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or mild disease Foundayo also reduced sleep apnea-specific hypoxic burden by up to an average of 55.9%, improving oxygen levels during sleep Lilly plans to submit Foundayo to the U.S. FDA for moderate-to-severe obstructive sleep apnea by the end of 2026 INDIANAPOLIS , Nov. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight, with and without the use of positive airway pressure (PAP) therapy. At 52 weeks, Foundayo met the primary endpoint, significantly reducing the apnea-hypopnea index (AHI), the standard measure of sleep apnea severity, as well as improving weight and other cardiovascular risk factors. 1 The results were presented today at the American Heart Association (AHA) Scientific Sessions 2026 and simultaneously published in JAMA . OSA affects an estimated 936 million adults worldwide, and most have never been diagnosed. 2 In people with OSA, the airway repeatedly collapses during sleep, causing drops in...",
    "product": "Foundayo",
    "summary": "Eli Lilly and Company announced positive Phase 3 clinical trial results for Foundayo (orforglipron) for the treatment of moderate-to-severe obstructive sleep apnea.",
    "location": "Indianapolis, Indiana, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA3061337&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "Foundayo",
      "full_text": "Foundayo (orforglipron)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-09T14:30:00Z",
    "location_data": [
      {
        "city": "Indianapolis",
        "state": "Indiana",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-09",
    "article_sentence": "Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight, with and without the use of positive airway pressure (PAP) therapy."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.